Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis.
about
A Review of the Mechanisms of Blood-Brain Barrier Permeability by Tissue-Type Plasminogen Activator Treatment for Cerebral IschemiaImpacts of tissue-type plasminogen activator (tPA) on neuronal survivalDendrimer advances for the central nervous system delivery of therapeuticsImprovement of Psychotic Symptoms and the Role of Tissue Plasminogen ActivatorDysfunction in the coagulation system and schizophreniaNorrin attenuates protease-mediated death of transformed retinal ganglion cellsThe serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptorsNeuroserpin polymorphisms and stroke risk in a biracial population: the stroke prevention in young women studyIncreased Serum PAI-1 Levels in Subjects with Metabolic Syndrome and Long-Term Adverse Mental Symptoms: A Population-Based StudyPlasminogen activator inhibitor type 1 derived peptide, EEIIMD, diminishes cortical infarct but fails to improve neurological function in aged rats following middle cerebral artery occlusionMolecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activatorImpaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's diseasePlasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?Combination treatment of r-tPA and an optimized human apyrase reduces mortality rate and hemorrhagic transformation 6h after ischemic stroke in aged female rats.Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid β-peptide elimination from the brainThe contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicityExogenous t-PA administration increases hippocampal mature BDNF levels. plasmin- or NMDA-dependent mechanism?Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's diseaseDesmoteplase: discovery, insights and opportunities for ischaemic stroke.Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit.Relevance of Post-Stroke Circulating BDNF Levels as a Prognostic Biomarker of Stroke Outcome. Impact of rt-PA Treatment.Tissue-type plasminogen activator has a neuroprotective effect in the ischemic brain mediated by neuronal TNF-α.Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein mediate cerebral ischemia-induced nuclear factor-kappaB pathway activation.Endothelial cells and astrocytes: a concerto en duo in ischemic pathophysiology.Adipokines and the blood-brain barrierThe neurovascular unit and combination treatment strategies for strokeCleavage of the NR2B subunit amino terminus of N-methyl-D-aspartate (NMDA) receptor by tissue plasminogen activator: identification of the cleavage site and characterization of ifenprodil and glycine affinities on truncated NMDA receptor.Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities.The plasminogen activator system modulates sympathetic nerve function.Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease.Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease.Regulated intramembrane proteolysis of the low-density lipoprotein receptor-related protein mediates ischemic cell deathBlood-brain barrier transport of therapeutics via receptor-mediationTissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brainNeuroprotection and stroke: time for a compromise.uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPKThe low-density lipoprotein receptor-related protein 1 mediates tissue-type plasminogen activator-induced microglial activation in the ischemic brainAge and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact.Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier.LRP1 assembles unique co-receptor systems to initiate cell signaling in response to tissue-type plasminogen activator and myelin-associated glycoprotein.
P2860
Q26772837-55D1C9A1-9DAA-4FB1-89C1-D56296B67E0DQ26777261-B1E78C99-627F-41A1-B2A7-4BF1A9BD4F7FQ26828423-C61A7AEE-550F-45E9-B0AD-EFCB9F8A16BDQ26828527-E978AAA3-EDE4-466C-8FE9-68CC94960D2AQ28068412-2B64BDD2-124E-4C74-8C03-404F214A390FQ28575390-0FBD42E8-BA6F-49E2-A3B1-D93F8E5D032BQ28771352-BC40B5CF-247A-4CE8-A46C-C75754696286Q33303923-0381D7D0-5382-4363-B0C9-1EFB9DD95A48Q33726132-2F11444C-D6DC-4174-A1C0-DB905AF16DE2Q33767438-C8DD2D66-0CA8-4C09-B301-E07FEA37FA62Q33823616-1A5B773A-D741-4CFF-903B-18B44138807EQ33895840-1AAF1A3B-DE6C-4690-BB20-3BFC94915ED8Q34018715-8D75A951-6946-47E4-BCC2-8DA6D3C99C15Q34020021-44E15536-0901-4B1B-99C1-C3FF274BF073Q34274025-87E75DC0-D928-4415-BD92-FAA2435C87BFQ34504984-8F3E5B66-D990-42A4-A298-123C1164DD6CQ35132128-9FEE1A86-95AC-4FC3-8FC4-1A169D0C673BQ35559895-E421B2CA-6893-429F-B60F-4F2218506E65Q35657910-B85DBB09-A52C-4683-99FE-D7A742F49E4AQ35751067-87D6CCDF-9F38-46EC-8908-FC0679A60EC2Q35808437-8CA18340-9260-4B62-BD3D-86BAF222DA61Q35880850-9378E6CE-F2B2-45BE-A9C7-F966423AF06CQ36007453-2642CE93-0640-4778-8014-306882CFBB7CQ36072867-E8EED7DA-6458-4A10-9F94-CA1B964EE3BAQ36088883-90FB9611-1E69-4E93-8064-7336E916159DQ36124038-B9E8D8BB-7302-4BF3-B502-776BCD6563EEQ36127093-3C0E717E-AE35-4C74-9811-8FBB26ACBF35Q36205039-0C54DF04-7DCD-4A1A-A28E-9780C0CD9B03Q36228900-991F9176-7AA1-45CB-A453-9959E55C2972Q36229619-4D180FF7-D2FF-42ED-8355-5454F93498CCQ36330297-A19A3902-9DDC-41A9-AC27-A3A372011707Q36579857-3B970065-977C-489E-9247-36260B477479Q36874295-766FDE5D-E540-4173-8D78-3CD67CA15C63Q36915885-78D49F9D-84C9-4816-AF80-8F916C8D8184Q36922560-4F6010D6-D2BC-4B66-A135-A9DE87A0DC77Q36948533-C6FFA4C4-DEC8-4943-8212-0F6AFA7F1363Q37071903-CB914445-77A5-4342-8298-F01D3CDED851Q37270632-4BF19382-D586-47C3-8A31-AFA21F0FBA12Q37312010-8A7711A5-33D4-4835-85F8-7F51C0489F38Q37333802-DAE5CE69-65EF-4C94-9BDD-BA2A1B1459DB
P2860
Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Tissue-type plasminogen activa ...... protein-mediated transcytosis.
@en
Tissue-type plasminogen activa ...... protein-mediated transcytosis.
@nl
type
label
Tissue-type plasminogen activa ...... protein-mediated transcytosis.
@en
Tissue-type plasminogen activa ...... protein-mediated transcytosis.
@nl
prefLabel
Tissue-type plasminogen activa ...... protein-mediated transcytosis.
@en
Tissue-type plasminogen activa ...... protein-mediated transcytosis.
@nl
P2093
P50
P1433
P1476
Tissue-type plasminogen activa ...... protein-mediated transcytosis.
@en
P2093
André Nouvelot
Julien Chuquet
Mónica Fernández-Monreal
Omar Touzani
Vincent Berezowski
P304
P356
10.1161/01.CIR.0000163542.48611.A2
P407
P50
P577
2005-04-25T00:00:00Z